Invivo Rat anti-Mouse CD276 Recombinant mAb

產(chǎn)品型號(hào)：S0B1361

更新時(shí)間：2025-10-11

廠(chǎng)商性質(zhì)：生產(chǎn)廠(chǎng)家

訪(fǎng)問(wèn)量：322

服務(wù)熱線(xiàn)

15855403091

立即咨詢(xún)

產(chǎn)品分類(lèi)

PRODUCT CLASSIFICATION

抗體/抗原

ELISA試劑盒抗體試劑盒二抗試劑盒二抗其它流式抗體瓊脂糖/磁珠偶聯(lián)抗體抗Payload抗體泛修飾抗體標(biāo)簽/內(nèi)參抗體功能性抗體 Biosimilar抗體偶聯(lián)抗體配對(duì)抗體病理/IHC抗體

查看全部產(chǎn)品

相關(guān)文章

功能性抗體：如何解鎖其在生物醫(yī)學(xué)研究中的無(wú)限潛能？

斯達(dá)特特色產(chǎn)品推薦之：PD-1 功能性抗體

DT3C賦能ADC藥物研發(fā)：高效檢測(cè)抗體內(nèi)化效率

TDP-43與漸凍癥：守護(hù)or背叛？

產(chǎn)品介紹

CD276 （B7-H3） is an immune checkpoint molecule belonging to the B7 family and encodes a type I transmembrane protein. It plays a role in regulating T cell-mediated immune responses. CD276 is highly expressed in various tumor cells and tumor-infiltrating immune cells, aiding tumor cells in evading immune surveillance and promoting tumor proliferation, metastasis, and treatment resistance. Additionally, CD276 is associated with cancer stem cell properties, and its high expression is linked to poor prognosis. Currently, several targeted therapies against CD276, including monoclonal antibodies, bispecific antibodies, antibody-drug conjugates （ADCs）, and CAR-T cell therapies, are under development and in clinical trials, showing promising anti-tumor potential.

上一個(gè)：S0B4059Goat Anti-Mouse IgG (H+L) (min X Hu, Bov Sr Prot)